Yakult begins ThermoDox trials as pharma sales rise
This article was originally published in Scrip
Executive Summary
Following its acquisition of Japanese rights last year, Yakult Honsha has joined a global Phase III trial programme for Celsion's doxorubicin product ThermoDox in primary liver cancer.